Boston Scientific Corporation (BSX) has had multiple notable developments recently. In a mix of favorable and adverse news, the firm has seen its stock move by -1.55% but also has outperformed the healthcare sector. It has announced its Q1 2025 earnings date, with the CEO and CFO detailing their 2025 performance, and the results for Q4 2024 have shown record revenue growth. The stock is seeing strong growth, with investors becoming more bullish, pushing the stock growth to 5.6% this week. BSX has faced pressure from new tariffs, completed a €1.5 billion offering of senior notes, and made agreements to acquire
SoniVie Ltd and
Cortex, Inc. Product launches and international expansion have lent support to BSX, and the firm has received FDA clearance for its
Bolt IVL system. Despite earnings trending downwards over the past five years, the stock has advanced 3.8%, bringing five-year gains to 224%. There are concerns over whether its fundamentals support the strong stock performance, but current momentum remains high. Forecasts peg a double-digit sales increase in 2025.
Boston Scientific Corp BSX News Analytics from Tue, 10 Sep 2024 07:00:00 GMT to Thu, 03 Apr 2025 22:00:13 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 1
